Sugi Predict

Sugi Predict / Targets / MAP3K20

MAP3K20

Mitogen-activated protein kinase kinase kinase 20 · Q9NYL2 · MAP3K20 on Sugi Atlas →

44,351 patent compounds predicted against MAP3K20, 34,822 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL232042 SCHEMBL232042 1.00 4/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 3/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
Sorafenib Sorafenib (SCHEMBL19322) 0.80 3/20
SCHEMBL257980 SCHEMBL257980 0.74 3/20
SCHEMBL171259 SCHEMBL171259 0.64 3/20
SCHEMBL171188 SCHEMBL171188 0.61 3/20
SCHEMBL171273 SCHEMBL171273 0.61 3/20
SCHEMBL171257 SCHEMBL171257 0.59 3/20
SCHEMBL171237 SCHEMBL171237 0.57 3/20
SCHEMBL171244 SCHEMBL171244 0.57 3/20
SCHEMBL257963 SCHEMBL257963 0.57 3/20
SCHEMBL169271 SCHEMBL169271 0.55 3/20
SCHEMBL171216 SCHEMBL171216 0.55 3/20
SCHEMBL171054 SCHEMBL171054 0.53 3/20
SCHEMBL169278 SCHEMBL169278 0.53 3/20
SCHEMBL171345 SCHEMBL171345 0.53 3/20
SCHEMBL171268 SCHEMBL171268 0.51 3/20
SCHEMBL171350 SCHEMBL171350 0.51 3/20
SCHEMBL171196 SCHEMBL171196 0.50 3/20

Clinical trials — most relevant to MAP3K20 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
BKM120 For Triple Negative Breast Cancer PHASE2COMPLETED
A Study of Mirdametinib in People With Central Nervous System Tumors PHASE1/PHASE2RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP3K20 binder may also engage these)

ProteinNameSimilarity
Q9ESL4 — 1.000 Q9ESL4 →
P28028 — 0.987 P28028 →
Q8BWW9 — 0.987 Q8BWW9 →
P34908 — 0.987 P34908 →
Q04982 — 0.986 Q04982 →
Q8QFR2 — 0.984 Q8QFR2 →
PKN2 Serine/threonine-protein kinase N2 0.984 landscape →
Q9UPW5 — 0.982 Q9UPW5 →
A7MBL8 — 0.982 A7MBL8 →
Q8K1Y2 — 0.982 Q8K1Y2 →
Q3LAC4 — 0.982 Q3LAC4 →
Q641K1 — 0.982 Q641K1 →
Q5U252 — 0.982 Q5U252 →
Q8CGF6 — 0.981 Q8CGF6 →
BRAF Serine/threonine-protein kinase B-raf 0.981 landscape →
Q66H91 — 0.980 Q66H91 →
Q8VDD9 — 0.980 Q8VDD9 →
P38438 — 0.980 P38438 →
Q8WWQ0 — 0.980 Q8WWQ0 →
O08874 — 0.980 O08874 →
Q8IWR0 — 0.979 Q8IWR0 →
Q14161 — 0.979 Q14161 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.979 landscape →
O94967 — 0.979 O94967 →
Q920M7 — 0.979 Q920M7 →
O75563 — 0.979 O75563 →
Q3UGM2 — 0.979 Q3UGM2 →
PRKD1 Serine/threonine-protein kinase D1 0.978 landscape →
P48553 — 0.978 P48553 →
Q69ZK0 — 0.978 Q69ZK0 →